Immunotherapy IRC @fredhutch

The Immunotherapy Integrated Research Center accelerates discovery by promoting cross-disciplinary and cross-divisional collaboration @fredhutch.

[Immunotherapy IRC @fredhutch @FH_IRC]

First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies | Journal of Clinical Oncology https://t.co/hpcijVOoHI
@fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

Strengthening Individual-Patient Treatment Prediction in Precision Oncology: The Case for a National Evidence Infrastructure | Journal of Clinical Oncology https://t.co/i1NyLqLM8Z @fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and B... https://t.co/81UhcE0wYc @fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

Congrats to the IIRC Team for another great Thomas Symposium!

[Fred Hutch Cancer Center @fredhutch]

From bone marrow transplantation to T-cell immunotherapy, the legacy of Dr. E. Donnall Thomas continues to shape cancer care. This week, researchers from around the world gathered in Seattle for the inaugural Dr. E. Donnall Thomas Symposium. 📸

[Immunotherapy IRC @fredhutch @FH_IRC]

Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma | Science Translational Medicine https://t.co/nAfgFxyHbz
@HutchInnovation @fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

Fixed-treatment duration venetoclax following covalent BTKi progressio… https://t.co/iTUjpY9jen
@fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation https://t.co/tYdHbyEY6f
@fredhutch

[Fred Hutch Cancer Center @fredhutch]

Fred Hutch is recruiting an open-rank faculty member in cancer immunotherapy. Join a leading immunotherapy research community and help advance next-generation treatments from discovery to clinical translation. Apply: https://t.co/k366K2CcYo

[Immunotherapy IRC @fredhutch @FH_IRC]

Uneven TCR chain pairing constraints govern epitope recognition | Science https://t.co/2CPTlfi7Lz
@fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

JCI - B-cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma https://t.co/EwVELYTcPU @fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

The Clues Hidden in Failed Prostate Cancer Trials

[Immunotherapy IRC @fredhutch @FH_IRC]

CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model https://t.co/wGzs614DmI 1/2014/533073/CD45-Directed-Radioimmunotherapy-with-the-Alpha . @fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

Researchers optimized a method to isolate nuclei from flash‑frozen mouse colon tissue for single‑nuclei RNA sequencing using  Miltennyi’s lysis buffer and Octo-dissociator with chillers. The protocol improved nuclei RNA quality and counting prior to fixing nuclei for the 10x. FLEX- Multiplex protocol, supporting high‑quality, cost-effective molecular profiling when other single‑cell methods aren’t possible. @HutchInnovation https://t.co/5cK7k8BZkM

[Aaron Ring @aaronmring]

Autoantibodies cause autoimmune disease, shape infection outcomes, and alter cancer immunotherapy. But what role might they play in neuropsychiatric disease? In our new preprint, Katlyn Nemani and @JillianRJaycox take on this question in schizophrenia. 🧵
https://t.co/lmL4sx7QSz

[Aaron Ring @aaronmring]

T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too?

That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below

https://t.co/VgTByRKRCX

[Immunotherapy IRC @fredhutch @FH_IRC]

https://t.co/y9JwNWhqI6 In 4,258 patients, donor age affected outcomes differently depending on donor type. @fredhutch researchers & collaborators found while younger family donors showed rising risk once donors were ~38, matched unrelated donors stayed low‑risk until ~50 with better overall survival, allowing for more personalized donor choices.

[Immunotherapy IRC @fredhutch @FH_IRC]

https://t.co/PE42SewseP via @fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

CAR‑T saves lives but can disrupt humoral immunity. New data show CD19/20 CAR‑T recipients often lack protective antibodies to ~1/3 of vaccine‑preventable pathogens for up to a year, with even larger gaps after BCMA CAR‑T. Re‑vaccination helps—especially in patients with higher B‑cell counts. @fredhutch
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response | Nature Communications

[Immunotherapy IRC @fredhutch @FH_IRC]

PhD (or equivalent) students within 2 years of graduation or who have graduated in the last year - Apply to visit with faculty at @FredHutch and hear about opportunities at this world-renowned institution. Food, lodging and travel covered! Apply by June 1: https://t.co/AGzR7hRzQO